Tyler Martinson, Megan J Heise, Kevin Sassaman, Hannah R Schmidt, Alexa B D'Angelo, Shivani Mahuvakar, Dustin T Duncan, Keith J Horvath, Sabina Hirshfield, Renessa Williams, Mallory O Johnson, Christian Grov, Adam Carrico, Monica Gandhi, Matthew A Spinelli
{"title":"美国男男性接触者中对doxyPEP的认识和吸收的兴趣和差异。","authors":"Tyler Martinson, Megan J Heise, Kevin Sassaman, Hannah R Schmidt, Alexa B D'Angelo, Shivani Mahuvakar, Dustin T Duncan, Keith J Horvath, Sabina Hirshfield, Renessa Williams, Mallory O Johnson, Christian Grov, Adam Carrico, Monica Gandhi, Matthew A Spinelli","doi":"10.1097/QAD.0000000000004192","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The CDC recommends doxycycline post-exposure prophylaxis (doxyPEP) for men who have sex with men (MSM) with a bacterial sexually transmitted infection (bSTI) in the past year. This study explored determinants of doxyPEP awareness and uptake, and associations with HIV care outcomes, among U.S. MSM living with HIV.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Methods: </strong>From 10/2023-10/2024, we enrolled 827 MSM living with HIV from 46 states, Washington, D.C., and Puerto Rico via a popular geospatial networking app. Adjusted multivariable logistic regression examined determinants of doxyPEP awareness/use and associations with HIV treatment adherence, viral suppression, and care engagement.</p><p><strong>Results: </strong>Among 827 participants, 13% were currently taking doxyPEP, 46% were aware of doxyPEP but not prescribed it, and 41% had not heard of it. Of 360 participants CDC-eligible for doxyPEP, 20% were prescribed it, 49% had heard of it but were not on it, and 31% were unaware, 95% of whom expressed interest. Neither awareness nor use of doxyPEP was associated with HIV care outcomes. Both awareness and uptake of doxyPEP were higher among participants with a recent bSTI (adjusted odds ratio (aOR) = 1.15, 95%CI: 1.06-1.25; aOR = 1.11, 95%CI: 1.05-1.17, respectively) and lower in the U.S. Midwest, Mountain, and South regions (inverse-variance weighted average (IVW-Avg) aOR = 0.81, 95%CI: 0.76-0.86; IVW-Avg aOR = 0.86, 95%CI: 0.82-0.90, respectively) relative to Pacific states.</p><p><strong>Conclusions: </strong>High doxyPEP interest underscores unmet demand in integrated HIV/sexual health care. Sociodemographic and geographic disparities in doxyPEP implementation necessitate targeted interventions for MSM living with HIV to optimize impact on the bSTI epidemic.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interest and disparities in awareness and uptake of doxyPEP among U.S. MSM living with HIV.\",\"authors\":\"Tyler Martinson, Megan J Heise, Kevin Sassaman, Hannah R Schmidt, Alexa B D'Angelo, Shivani Mahuvakar, Dustin T Duncan, Keith J Horvath, Sabina Hirshfield, Renessa Williams, Mallory O Johnson, Christian Grov, Adam Carrico, Monica Gandhi, Matthew A Spinelli\",\"doi\":\"10.1097/QAD.0000000000004192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The CDC recommends doxycycline post-exposure prophylaxis (doxyPEP) for men who have sex with men (MSM) with a bacterial sexually transmitted infection (bSTI) in the past year. This study explored determinants of doxyPEP awareness and uptake, and associations with HIV care outcomes, among U.S. MSM living with HIV.</p><p><strong>Design: </strong>Cross-sectional study.</p><p><strong>Methods: </strong>From 10/2023-10/2024, we enrolled 827 MSM living with HIV from 46 states, Washington, D.C., and Puerto Rico via a popular geospatial networking app. Adjusted multivariable logistic regression examined determinants of doxyPEP awareness/use and associations with HIV treatment adherence, viral suppression, and care engagement.</p><p><strong>Results: </strong>Among 827 participants, 13% were currently taking doxyPEP, 46% were aware of doxyPEP but not prescribed it, and 41% had not heard of it. Of 360 participants CDC-eligible for doxyPEP, 20% were prescribed it, 49% had heard of it but were not on it, and 31% were unaware, 95% of whom expressed interest. Neither awareness nor use of doxyPEP was associated with HIV care outcomes. Both awareness and uptake of doxyPEP were higher among participants with a recent bSTI (adjusted odds ratio (aOR) = 1.15, 95%CI: 1.06-1.25; aOR = 1.11, 95%CI: 1.05-1.17, respectively) and lower in the U.S. Midwest, Mountain, and South regions (inverse-variance weighted average (IVW-Avg) aOR = 0.81, 95%CI: 0.76-0.86; IVW-Avg aOR = 0.86, 95%CI: 0.82-0.90, respectively) relative to Pacific states.</p><p><strong>Conclusions: </strong>High doxyPEP interest underscores unmet demand in integrated HIV/sexual health care. Sociodemographic and geographic disparities in doxyPEP implementation necessitate targeted interventions for MSM living with HIV to optimize impact on the bSTI epidemic.</p>\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000004192\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004192","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Interest and disparities in awareness and uptake of doxyPEP among U.S. MSM living with HIV.
Objective: The CDC recommends doxycycline post-exposure prophylaxis (doxyPEP) for men who have sex with men (MSM) with a bacterial sexually transmitted infection (bSTI) in the past year. This study explored determinants of doxyPEP awareness and uptake, and associations with HIV care outcomes, among U.S. MSM living with HIV.
Design: Cross-sectional study.
Methods: From 10/2023-10/2024, we enrolled 827 MSM living with HIV from 46 states, Washington, D.C., and Puerto Rico via a popular geospatial networking app. Adjusted multivariable logistic regression examined determinants of doxyPEP awareness/use and associations with HIV treatment adherence, viral suppression, and care engagement.
Results: Among 827 participants, 13% were currently taking doxyPEP, 46% were aware of doxyPEP but not prescribed it, and 41% had not heard of it. Of 360 participants CDC-eligible for doxyPEP, 20% were prescribed it, 49% had heard of it but were not on it, and 31% were unaware, 95% of whom expressed interest. Neither awareness nor use of doxyPEP was associated with HIV care outcomes. Both awareness and uptake of doxyPEP were higher among participants with a recent bSTI (adjusted odds ratio (aOR) = 1.15, 95%CI: 1.06-1.25; aOR = 1.11, 95%CI: 1.05-1.17, respectively) and lower in the U.S. Midwest, Mountain, and South regions (inverse-variance weighted average (IVW-Avg) aOR = 0.81, 95%CI: 0.76-0.86; IVW-Avg aOR = 0.86, 95%CI: 0.82-0.90, respectively) relative to Pacific states.
Conclusions: High doxyPEP interest underscores unmet demand in integrated HIV/sexual health care. Sociodemographic and geographic disparities in doxyPEP implementation necessitate targeted interventions for MSM living with HIV to optimize impact on the bSTI epidemic.
期刊介绍：
Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
